275 related articles for article (PubMed ID: 25173087)
1. Rotigotine: the first new chemical entity for transdermal drug delivery.
McAfee DA; Hadgraft J; Lane ME
Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
[TBL] [Abstract][Full Text] [Related]
2. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
3. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
5. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
Sixel-Döring F; Trenkwalder C
Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Ferini-Strambi L; Marelli S; Galbiati A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
[TBL] [Abstract][Full Text] [Related]
9. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine Schwarz Pharma.
Mucke HA
IDrugs; 2003 Sep; 6(9):894-9. PubMed ID: 12964070
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacology sheet. Transdermal Rotigotine (Neupro)].
J Pharm Belg; 2010 Jun; (2):49-50. PubMed ID: 20623986
[No Abstract] [Full Text] [Related]
12. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
Garnock-Jones KP
Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
Kenney C; Jankovic J
Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
[TBL] [Abstract][Full Text] [Related]
14. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine for restless legs syndrome.
Davies S
Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
[TBL] [Abstract][Full Text] [Related]
17. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
[TBL] [Abstract][Full Text] [Related]
18. Rotigotine: Parkinson's disease: a step backward.
Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design.
Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782
[No Abstract] [Full Text] [Related]
20. Drug safety evaluation of rotigotine.
Sprenger FS; Seppi K; Poewe W
Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
